Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tourmaline Bio, Inc. - Common Stock (NQ:TRML)

16.42 -0.29 (-1.74%)
Streaming Delayed Price Updated: 10:48 AM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tourmaline Bio, Inc. - Common Stock

Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Present at Upcoming Investor Conferences
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Present at Upcoming Investor Conferences
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
From Avalo Therapeutics
Via GlobeNewswire
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Announces Proposed Public Offering of Common Stock
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)
From Tourmaline Bio, Inc.
Via GlobeNewswire
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio. 
Via MarketBeat
Tourmaline Bio added to the NASDAQ Biotechnology Index
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
From Tourmaline Bio, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.